Novel classification system for walled-off necrosis: a step toward standardized nomenclature and risk-stratification framework.


Journal

Gastrointestinal endoscopy
ISSN: 1097-6779
Titre abrégé: Gastrointest Endosc
Pays: United States
ID NLM: 0010505

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 16 05 2022
revised: 07 09 2022
accepted: 23 09 2022
pubmed: 9 10 2022
medline: 25 1 2023
entrez: 8 10 2022
Statut: ppublish

Résumé

The optimal therapeutic approach for walled-off necrosis (WON) is not fully understood, given the lack of a validated classification system. We propose a novel and robust classification system based on radiologic and clinical factors to standardize the nomenclature, provide a framework to guide comparative effectiveness trials, and inform the optimal WON interventional approach. This was a retrospective analysis of patients who underwent endoscopic management of WON by lumen-apposing metal stent placement at a tertiary referral center. Patients were classified according to the proposed QNI classification system: quadrant ("Q"), represented an abdominal quadrant distribution; necrosis ("N"), denoted by the percentage of necrosis of WON; and infection ("I"), denoted as positive blood culture and/or systemic inflammatory response syndrome reaction with a positive WON culture. Two blinded reviewers classified all patients according to the QNI system. Patients were then divided into 2 groups: those with a lower QNI stratification (≤2 quadrants and ≤30% necrosis; group 1) and those with a higher stratification (≥3 quadrants, 2 quadrants with ≥30% necrosis, or 1 quadrant with >60% necrosis and infection; group 2). The primary outcome was mean time to WON resolution. Secondary procedural and clinical outcomes between the groups were compared. Seventy-one patients (75% men) were included and stratified by the QNI classification; group 1 comprised 17 patients and group 2, 54 patients. Patients in group 2 had a higher number of necrosectomies, longer hospital stays, and more readmissions. The mean time to resolution was longer in group 2 than in group 1 (79.6 ± 7.76 days vs 48.4 ± 9.22 days, P = .02). The mortality rate was higher in group 2 (15% vs 0%, P = .18). Despite the heterogeneous nature of WON in severe acute pancreatitis, a proposed QNI system may provide a standardized framework for WON classification to inform clinical trials, risk-stratify the disease course, and potentially inform an optimal management approach.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
The optimal therapeutic approach for walled-off necrosis (WON) is not fully understood, given the lack of a validated classification system. We propose a novel and robust classification system based on radiologic and clinical factors to standardize the nomenclature, provide a framework to guide comparative effectiveness trials, and inform the optimal WON interventional approach.
METHODS METHODS
This was a retrospective analysis of patients who underwent endoscopic management of WON by lumen-apposing metal stent placement at a tertiary referral center. Patients were classified according to the proposed QNI classification system: quadrant ("Q"), represented an abdominal quadrant distribution; necrosis ("N"), denoted by the percentage of necrosis of WON; and infection ("I"), denoted as positive blood culture and/or systemic inflammatory response syndrome reaction with a positive WON culture. Two blinded reviewers classified all patients according to the QNI system. Patients were then divided into 2 groups: those with a lower QNI stratification (≤2 quadrants and ≤30% necrosis; group 1) and those with a higher stratification (≥3 quadrants, 2 quadrants with ≥30% necrosis, or 1 quadrant with >60% necrosis and infection; group 2). The primary outcome was mean time to WON resolution. Secondary procedural and clinical outcomes between the groups were compared.
RESULTS RESULTS
Seventy-one patients (75% men) were included and stratified by the QNI classification; group 1 comprised 17 patients and group 2, 54 patients. Patients in group 2 had a higher number of necrosectomies, longer hospital stays, and more readmissions. The mean time to resolution was longer in group 2 than in group 1 (79.6 ± 7.76 days vs 48.4 ± 9.22 days, P = .02). The mortality rate was higher in group 2 (15% vs 0%, P = .18).
CONCLUSIONS CONCLUSIONS
Despite the heterogeneous nature of WON in severe acute pancreatitis, a proposed QNI system may provide a standardized framework for WON classification to inform clinical trials, risk-stratify the disease course, and potentially inform an optimal management approach.

Identifiants

pubmed: 36208794
pii: S0016-5107(22)02017-X
doi: 10.1016/j.gie.2022.09.019
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

300-308

Informations de copyright

Copyright © 2023 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Auteurs

Serge Baroud (S)

Department of Internal Medicine, MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio, USA.

Vinay Chandrasekhara (V)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Andrew C Storm (AC)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Ryan J Law (RJ)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Eric J Vargas (EJ)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Michael J Levy (MJ)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Tala Mahmoud (T)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Fateh Bazerbachi (F)

St Cloud Interventional Endoscopy Program, CentraCare, St Cloud Hospital, St Cloud, Minnesota, USA.

Aliana Bofill-Garcia (A)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Rabih Ghazi (R)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Daniel B Maselli (DB)

Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

John A Martin (JA)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Santhi Swaroop Vege (SS)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Naoki Takahashi (N)

Division of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

Bret T Petersen (BT)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Mark D Topazian (MD)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Barham K Abu Dayyeh (BK)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH